궤양성 대장염의 최신치료
Advances in ulcerative colitis therapy
2
조회
0
다운로드
16
인용
0
참고문헌
키워드
초록
Ulcerative colitis is an idiopathic inflammatory bowel disease characterized by colonic mucosal inflammation and chronic relapsing episodes. The initial therapeutic approach depends on both the extent of colonic involvement and the severity of the disease process at presentation. The mainstay of ulcerative colitis therapy is the administration of 5-aminosalicylic acid (5-ASA) or steroid. Additional medical therapy or colectomy should be considered if the patient remains symptomatic despite conventional therapy, regardless of the extent of colonic involvement. Cyclosporins are effective as a short-term rescue therapy for steroid-refractory ulcerative colitis. Recently, new 5-ASA and steroid formulations with altered delivery, dosing regimens, and less frequent administration have been introduced and demonstrated to be efficacious in active mild to moderate colitis. Infliximab is given to try to avoid the need for colectomy and has proven efficacious in ulcerative colitis. This review outlines the standard therapy for ulcerative colitis and discusses new insights into the recent trend focusing on new therapies, including biological agents and leukocytapheresis.
Abstract
Ulcerative colitis is an idiopathic inflammatory bowel disease characterized by colonic mucosal inflammation and chronic relapsing episodes. The initial therapeutic approach depends on both the extent of colonic involvement and the severity of the disease process at presentation. The mainstay of ulcerative colitis therapy is the administration of 5-aminosalicylic acid (5-ASA) or steroid. Additional medical therapy or colectomy should be considered if the patient remains symptomatic despite conventional therapy, regardless of the extent of colonic involvement. Cyclosporins are effective as a short-term rescue therapy for steroid-refractory ulcerative colitis. Recently, new 5-ASA and steroid formulations with altered delivery, dosing regimens, and less frequent administration have been introduced and demonstrated to be efficacious in active mild to moderate colitis. Infliximab is given to try to avoid the need for colectomy and has proven efficacious in ulcerative colitis. This review outlines the standard therapy for ulcerative colitis and discusses new insights into the recent trend focusing on new therapies, including biological agents and leukocytapheresis.
참고문헌 (48)
- Edwards FC, "The course and prognosis of ulcerative colitis: III. complications", Gut, 5, pp.1~22 (1964)
- Carter MJ, "Guidelines for the management of inflammatory bowel disease in adults", Gut, 53(5), pp.V1~V16 (2004)
- Kim SJ, "Two cases of ulcerative colitis", Korean J Gastroenterol, 2, pp.29~34 (1970)
- Yang SK, "Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong District, Seoul, Korea, 1986-1997", J Gastroenterol epatol, 15, pp.1037~1042 (2000)
- Yang SK, "Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study", Inflamm Bowel Dis, 14, pp.542~549 (2008)
- Stange EF, "The European consensus on ulcerative colitis: new horizons?", Gut, 57, pp.1029~1031 (2008)
- Caprilli R, "Current management of severe ulcerative colitis", Nat Clin Pract Gastroenterol Hepatol, 4, pp.92~101 (2007)
- Sutherland L, "Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis", Cochrane Database Syst Rev, pp.CD000544~ (2006)
- Myers B, "Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract", Gut, 28, pp.196~200 (1987)
- Dew MJ, "An oral preparation to release drugs in the human colon", Br J Clin Pharmacol, 14, pp.405~408 (1982)
- Hardy JG, "Evaluation of an entericcoated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease", Aliment Pharmacol Ther, 1, pp.273~280 (1987)
- Rasmussen SN, "5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans", Gastroenterology, 83, pp.1062~1070 (1982)
- Green JR, "Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis", Gastroenterology, 114, pp.15~22 (1998)
- Pruitt R, "Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis", Am J Gastroenterol, 97, pp.3078~3086 (2002)
- Kane SV, "Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis", Am J Gastroenterol, 96, pp.2929~2933 (2001)
- Kamm MA, "Once-daily, high-concentration MMX mesalamine in active ulcerative colitis", Gastroenterology, 132, pp.66~75 (2007)
- Lichtenstein GR, "Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis", Clin Gastroenterol Hepatol, 5, pp.95~102 (2007)
- Ng SC, "Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis", Aliment Pharmacol Ther, 28, pp.815~829 (2008)
- Lennard-Jones JE, "Prednisone as maintenance treatment for ulcerative colitis in remission", Lancet, 1, pp.188~189 (1965)
- Campieri M, "Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study", Aliment Pharmacol Ther, 17, pp.1471~1480 (2003)
- Rizzello F, "Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study", Aliment Pharmacol Ther, 16, pp.1109~1116 (2002)
- Biancone L, "Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study", Dig Liver Dis, 39, pp.329~337 (2007)
- Rhodes JM, "Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis", Aliment Pharmacol Ther, 27, pp.228~240 (2008)
- Jewell DP, "Azathioprine in ulcerative colitis: final report on controlled therapeutic trial", Br Med J, 4, pp.627~630 (1974)
- Sandborn WJ, "A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate", Am J Gastroenterol, 91, pp.423~433 (1996)
- Timmer A, "Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis", Cochrane Database Syst Rev, pp.CD000478~ (2007)
- Herrlinger K, "Azathioprine in chronic inflammatory bowel diseases: evidence base", Med Klin (Munich), 95, pp.201~206 (2000)
- Faubion WA Jr, "The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study", Gastroenterology, 121, pp.255~260 (2001)
- Cottone M, "Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis", Am J Gastroenterol, 96, pp.773~775
- Papadakis KA, "Outcome of cytomegalovirus infections in patients with inflammatory bowel disease", Am J Gastroenterol, 96, pp.2137~2142 (2001)
- Borel JF, "The discovery and development of cyclosporine (Sandimmune)", Transplant Proc, 23, pp.1867~1874
- Kountouras J, "Immunomodulatory benefits of cyclosporine A in inflammatory bowel disease", J Cell Mol Med, 8, pp.317~328 (2004)
- Ina K, "Suppressive effects of cyclosporine A on neutrophils and T cells may be related to therapeutic benefits in patients with steroid-resistant ulcerative colitis", Inflamm Bowel Dis, 8, pp.1~9 (2002)
- Lichtiger S, "Cyclosporine in severe ulcerative colitis refractory to steroid therapy", N Engl J Med, 330, pp.1841~1845 (1994)
- Shibolet O, "Cyclosporine A for induction of remission in severe ulcerative colitis", Cochrane Database Syst Rev, pp.CD004277~ (2005)
- Gisbert JP, "Systematic review: infliximab therapy in ulcerative colitis", Aliment Pharmacol Ther, 25, pp.19~37 (2007)
- Braegger CP, "Tumour necrosis factor alpha in stool as a marker of intestinal inflammation", Lancet, 339, pp.89~91 (1992)
- Murch SH, "Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease", Gut, 34, pp.1705~1709 (1993)
- Rutgeerts P, "Infliximab for induction and maintenance therapy for ulcerative colitis", N Engl J Med, 353, pp.2462~2476 (2005)
- Sandborn WJ, "Infliximab reduces colectomy in patients with moderate-to-severe-UC: colectomy analysis from ACT 1 and ACT 2", Gut, 56(III), pp.A26~ (2007)
- McCarthy DA, "Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease", Clin Exp Immunol, 86, pp.489~493 (1991)
- Meuret G, "Macrophage turnover in Crohn’s disease and ulcerative colitis", Gastroen, 74, pp.501~503 (1978)
- Sinha A, "Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis", N Engl J Med, 349, pp.350~357 (2003)
- Sawada K, "Mechanism of leukocytapheresis effect in the treatment of ulcerative colitis", Nihon Rinsho Meneki Gakkai Kaishi, 22, pp.469~474 (1999)
- Saniabadi AR, "Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy?", J Clin Apher, 20, pp.171~184 (2005)
- Sawada K, "Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column", Curr Pharm Des, 9, pp.307~321
- Sigurbjornsson FT, "Leukocytapheresis for the treatment of IBD", Nat Clin Pract Gastroenterol Hepatol, 5, pp.509~516 (2008)
- 김효종, "활동기 궤양성 대장염에 있어서 과립구흡착요법의 전향적 다기관 연구", 대한소화기학회지, 45(1), pp.34~44 (2005), 대한소화기학회